BHP Shares Fall as Jansen Potash Project Costs Surge 
Kingboard Holdings Shares Surge After HK$11.77 Billion Block Trade to Expand PCB and AI Supply Chain Business 
Frank Stronach Found Guilty of Sexual Assault and Indecent Assault in Ontario Court 
Samsung Gains Interest from BYD, Google, AMD as AI Chip Demand Strains TSMC Capacity 
John Jumper Leaves Google DeepMind for Anthropic Amid Intensifying AI Talent Race 
Trump Says Anthropic No Longer Seen as National Security Threat 
US-Iran De-Escalation Shifts Washington’s Focus to AI Regulation and Crypto Legislation 
Obayashi to Acquire Multiplex in $526M Expansion Deal 
SoftBank Shares Drop as OpenAI Losses and Rising Costs Spark Investor Concerns 
GM and Lockheed Martin Partner to Strengthen U.S. Defense Manufacturing Capacity 
TD Bank Expands Employee Monitoring Software to Boost Productivity Amid Privacy Concerns 
Chinese Social Media Giant Xiaohongshu Eyes Hong Kong IPO at Over $70 Billion Valuation 
SK Hynix Shares Hit Record High After Shipping Next-Generation HBM4E AI Memory Samples 
US Raises Concerns Over Possible ASML EUV Machine Transfer to China 
Apple Signals Product Price Hikes Amid Rising Memory Chip Costs 
Ukrainian Drone Makers Target Japan and Asia Defense Market 
Trump Administration Delays DeepSeek and CXMT Trade Blacklist Designations Amid U.S.-China Tensions 
REGULATED INFORMATION
GHENT, Belgium, Jan. 18, 2016 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), that it received a notification of shareholdings from Perceptive Advisors LLC.
The above shareholders notified Ablynx that they have exceeded the 5% threshold on 12 January 2016 and now hold 2,773,439 Ablynx shares, representing 5.06% of the current 54,812,374 outstanding Ablynx shares.
Full versions of all transparency notifications are available on Ablynx website, under the section Investors.
About Ablynx
Ablynx is a biopharmaceutical company engaged in the development of Nanobodies®, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has approximately 40 proprietary and partnered programmes in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie, Boehringer Ingelheim, Eddingpharm, Genzyme, Merck & Co., Inc., Merck KGaA, Novartis, Novo Nordisk and Taisho Pharmaceuticals. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.
For more information, please contact
Ablynx:
Dr Edwin Moses
CEO
t: +32 (0)9 262 00 07
m: +32 (0)473 39 50 68
e: [email protected]
Marieke Vermeersch
Associate Director Investor Relations
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e: [email protected]
Follow us on Twitter @AblynxABLX
Ablynx media relations Instinctif Partners:
Sue Charles, Daniel Gooch
London office
t: +44 (0)20 7866 7905
e: [email protected]
Belgium/Dutch and French language
Jim Rusagara
Brussels office
t: +32 (0)2 626 9500
e: [email protected]
Pdf version of the press release http://hugin.info/137912/R/1979283/725054.pdf
HUG#1979283
